Akums Drugs & Pharmaceuticals Ltd.
AKUMSNSEHealthcarePharmaceuticals & DrugsSmall Cap
₹604.7
▲ 0.5%
—
Composite
As a CDMO, the company produces an extensive range of dosage forms including tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, and gummies, among others. It also engages in the marketing of trade generic and products under its own brand through distributors and alternative channels across India.
Q-DITS fundamental score
—Composite
Growth
7
Profitability
33
Valuation
0
Quality
50
Solvency
70
Earnings
100
Key metrics
MCap
₹9.5K Cr
TTM PE
37.2x
Industry PE
38.2x
TTM EPS
₹16.21
Book Value
₹210.57
Face Value
₹2
Div Yield
0.5%
PEG
—
PB
2.2x
ROE
8.1%
ROCE
14.8%
EBITDA mgn
14.9%
D/E
0.02
Int. Cover
5.1x
Curr. Ratio
3.25x
EPS
₹16.67
Growth — CAGR across horizons
| Metric | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|
| Net Sales | 5.9% | — | — | — |
| EBITDA | 12.4% | — | — | — |
| Net Profit | -16.5% | — | — | — |
Score snapshot
Piotroski
5/9
Altman Z
2.72
Quality
49.8
Growth
6.5
Valuation
—
Earn. Qual
100
PEAD
+1
SURGE
+1
Revenue, profitability & returns
Revenue & Net Profit (₹ Cr)
RevenueNet Profit
Margins (%)
EBITDA%PAT%
Return ratios (%)
ROEROCEROA
Annual financials — last 10 years
Tap any row to see its trend
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ›RevenueCr | 1,857 | 1,552 | 2,008 | 2,414 | 2,723 | 3,672 | 3,655 | 4,178 | 4,118 | 4,359 | ↑ |
| ›EBITDACr | 204 | 214 | 204 | 200 | 249 | -82 | 310 | 131 | 533 | 631 | ↑ |
| ›EBITDA margin | 10.9% | 13.8% | 10.2% | 8.4% | 11.5% | -1.9% | 10.5% | 3.8% | 12.5% | 14.9% | ↑ |
| ›Net profitCr | 96 | 90 | 68 | 44 | 123 | -251 | 98 | 1 | 344 | 256 | ↓ |
| ›PAT margin | 5.1% | 5.8% | 3.4% | 1.8% | 4.5% | -6.8% | 2.7% | 0% | 8.3% | 5.9% | ↓ |
| ›EPS₹ | ₹7.39 | ₹7 | ₹5.26 | ₹3.34 | ₹8.57 | ₹-17.65 | ₹6.63 | ₹-0.28 | ₹22.09 | ₹16.67 | ↓ |
| ›Revenue growth | 12.5% | -16.4% | 29.4% | 20.2% | 12.8% | 34.9% | -0.5% | 14.3% | -1.4% | 5.8% | ↑ |
| ›PAT growth | 114.5% | -5.3% | -24.8% | -35.8% | 182.8% | -303.2% | 139% | -99.2% | 0% | -25.4% | ↓ |
| ›ROE | 14.3% | 12% | 8.2% | 5.5% | 15.4% | -33.3% | 14.6% | 0.1% | 18.3% | 8.1% | ↓ |
| ›ROCE | 18.1% | 17.3% | 14.2% | 13.2% | 19.1% | -18% | 17.6% | 0.4% | 17.8% | 14.8% | ↓ |
| ›ROA | 8.1% | 7% | 4.7% | 2.4% | 5.9% | -9.6% | 3.1% | 0% | 9.4% | 5.6% | ↓ |
| ›P/E | 0x | 0x | 0x | 0x | 0x | 0x | 0x | 0x | 21.5x | 28x | ↑ |
| ›P/B | 0x | 0x | 0x | 0x | 0x | 0x | 0x | 0x | 2.4x | 2.2x | ↓ |
| ›D/E | 0.3 | 0.2 | 0.3 | 0.2 | 0.1 | 0.6 | 0.7 | 0.7 | 0 | 0 | ↑ |
| ›Current ratio | 1.4x | 1.5x | 1.6x | 1.7x | 2x | 1.5x | 1.5x | 1.6x | 2.5x | 3.3x | ↑ |
| ›Interest cover | 10.2x | 12.7x | 6.6x | 6.7x | 26.5x | -10.6x | 4.2x | 0.1x | 11x | 5.1x | ↓ |
Quarterly results
Tap any row to see its trend
| Metric | 2023-12 | 2024-03 | 2024-06 | 2024-09 | 2024-12 | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ›RevenueCr | 1,083 | 944 | 1,019 | 1,033 | 1,010 | 1,056 | 1,024 | 1,018 | 1,160 | 1,158 | ↓ |
| ›Rev growth YoY | — | — | 5.1% | -12.5% | -6.7% | 11.8% | 0.5% | -1.5% | 14.8% | 9.7% | ↓ |
| ›EBITDACr | 93 | 3 | 128 | 121 | 121 | 94 | 129 | 94 | 147 | 152 | ↑ |
| ›EBITDA margin | 8.6% | 0.3% | 12.6% | 11.7% | 12% | 8.9% | 12.6% | 9.3% | 12.7% | 13.1% | ↑ |
| ›Net profitCr | 195 | -39 | 61 | 67 | 66 | 150 | 65 | 43 | 68 | 81 | ↑ |
| ›PAT growth YoY | — | — | 132.7% | 103.9% | -66% | 479.1% | 5.7% | -35.9% | 2.1% | -45.6% | ↓ |
| ›EPS₹ | ₹13.54 | ₹-2.89 | ₹4.21 | ₹4.26 | ₹4.26 | ₹9.64 | ₹4.15 | ₹2.66 | ₹4.33 | ₹5.53 | ↑ |
Balance sheet — last 10 years (₹ Cr)
Tap any row to see its trend
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ›Shareholders' equityCr | 711 | 795 | 856 | 722 | 885 | 622 | 717 | 710 | 3,047 | 3,313 | ↑ |
| ›ReservesCr | 710 | 794 | 855 | 721 | 884 | 608 | 689 | 681 | 3,016 | 3,283 | ↑ |
| ›Total borrowingsCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| ›InvestmentsCr | 23 | 38 | 49 | 92 | 93 | 107 | 110 | 66 | 71 | 83 | ↑ |
| ›Total assetsCr | 762 | 876 | 974 | 1,274 | 1,546 | 1,757 | 1,976 | 2,294 | 3,201 | 4,335 | ↑ |
| ›Current assetsCr | 574 | 701 | 833 | 1,250 | 1,157 | 1,864 | 1,879 | 1,941 | 2,275 | 3,560 | ↑ |
| ›Current liabilitiesCr | 417 | 480 | 525 | 730 | 580 | 1,272 | 1,266 | 1,211 | 894 | 1,095 | ↑ |
| ›Trade payablesCr | 147 | 244 | 210 | 423 | 341 | 590 | 567 | 532 | 643 | 602 | ↓ |
| ›Gross blockCr | 784 | 882 | 940 | 992 | 1,325 | 1,542 | 1,715 | 1,893 | 2,252 | 2,445 | ↑ |
Cash flow statement (₹ Cr)
Tap any row to see its trend
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ›Operating CF (CFO)Cr | 156 | 157 | -23 | 28 | 134 | 32 | 177 | 498 | 465 | 1,181 | ↑ |
| ›Investing CF (CFI)Cr | -128 | -111 | -49 | -190 | -109 | -235 | -305 | -330 | -548 | -930 | ↓ |
| ›Financing CF (CFF)Cr | -34 | -35 | 75 | 233 | -95 | 236 | 125 | -108 | 73 | 34 | ↓ |
| ›Net cash changeCr | -7 | 11 | 3 | 71 | -70 | 33 | -4 | 60 | -10 | 285 | ↑ |
| ›Closing cashCr | 7 | 18 | 21 | 92 | 22 | 55 | 52 | 111 | 101 | 386 | ↑ |
Cash flow components
CFO · CFI · CFF (₹ Cr)
CFOCFICFF
Q-DITS scorecard
Composite score
—
Quality (25%)49.8
Growth (25%)6.5
Valuation (20%)—
Piotroski (15%)56
Earnings Quality (10%)100
Momentum (5%)—
Weighted blend, rescaled to the components available for this stock.
Piotroski F-Score
5/9
✓ROA positiveROA 5.59%
✓CFO positiveCFO ₹1181.2 Cr
✗ROA improving9.42% → 5.59%
✓CFO > PAT (low accruals)CFO 1181.2 vs PAT 256.4
✗Leverage decreasedD/E 0.0 → 0.02
✓Liquidity improvedCR 2.54 → 3.25
✗No share dilutionEPS 22.09 → 16.67
✓Margin improvedEBITDA mgn 12.54% → 14.93%
✗Asset turnover upAsset TO 1.13 → 0.95
Altman Z-Scoregrey
2.72
X1
0.569
X2
0.757
X3
0.11
X4
0.764
X5
1.006
>2.9 safe · 1.23–2.9 grey · <1.23 distress
Quality
49.8/100
ROE
8.1%
ROCE
14.8%
Margin
5.9%
Debt
0
Int. cover
5.1x
Growth
6.5/100
Revenue 3Y
5.9%
Profit 3Y
-16.5%
EPS
-24.5%
Valuation
N/A
PE
—
PB
—
EV/EBITDA
—
Earnings quality
100/100
CFO₹1,181 Cr
PAT₹256 Cr
Accrual ratio-0.213
CFO/PAT4.61x
PEAD · SURGE
+1 / +1
Revenue SUE0.9
EPS SUE0.14
Latest quarter2026-03
Rev growth YoY9.7%
Documents & filings
Loading documents…
Peer comparison
| Company | MCap (Cr) | Revenue | PAT | PE | PB | ROE% | ROCE% | D/E |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,40,794 | 58,462 | 11,565 | 38.4x | 5.3x | 16.2 | 19.9 | 0.03 |
| Divi's Laboratories Ltd. | 1,78,956 | 10,560 | 2,568 | 69.7x | 10.7x | 15.4 | 20.5 | 0 |
| Torrent Pharmaceuticals Ltd. | 1,49,820 | 13,980 | 2,138 | 69.3x | 17.9x | 26.8 | 19.3 | 1.76 |
| Cipla Ltd. | 1,09,370 | 28,163 | 3,870 | 28.2x | 3.2x | 11.8 | 16 | 0.01 |
| Lupin Ltd. | 1,07,537 | 27,958 | 5,355 | 20.2x | 4.8x | 21.1 | 22 | 0.3 |
| Zydus Lifesciences Ltd. | 1,06,823 | 27,148 | 5,026 | 21.2x | 4x | 21.1 | 26.1 | 0.13 |
| Dr. Reddy's Laboratories Ltd. | 1,06,133 | 33,700 | 4,144 | 25.3x | 2.8x | 18.6 | 23.3 | 0.14 |